Full Text View
Tabular View
No Study Results Posted
Related Studies
Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
This study is ongoing, but not recruiting participants.
Study NCT00012363   Information provided by National Cancer Institute (NCI)
First Received: March 3, 2001   Last Updated: July 23, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Esophageal Cancer
Gastric Cancer
Additional conditions recognized in this trial
Esophageal Diseases
Esophageal Neoplasms
Stomach Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site
Stomach Diseases
Interventions listed in this trial
gemcitabine hydrochloride
irinotecan hydrochloride
Additional drug interventions recognized in this trial
Camptothecin
Gemcitabine
Irinotecan
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Southwest Oncology Group
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services